Abstract:IJS readers may be interested to know that intravenous (IV) thrombolysis has been used as a standard therapy in acute ischaemic stroke (IS) (1, 2). In the United States, tissue plasminogen activator (tPA) was approved for the treatment of acute IS in 1996, but its use has only recently been accepted by the Department of Medicine of Ho Chi Minh city (HCMC) in 2005. Since 2006, there are three hospitals in HCMC offering thrombolysis for acute IS. The major obstacles for treatment are the cost of drug and the limited therapeutic window, which requires public awareness and organised emergency management. The cost of thrombolysis in Vietnam is not subsidised by government or private insurance; therefore, it is only available for patients who can afford to pay for the drug. The three major stroke units in HCMC managed a total of 6171 patients with acute IS between May 2006 and May 2009. Of these, 121 patients (2%) received IV-tPA based on the inclusion and exclusion criteria of the NINDS study (1). Our study sample had a mean age of 57-years, and 46% were men. Hypertension was the most common vascular risk factor (61%), followed by atrial fibrillation (21%) and diabetes mellitus (17%). The leading TOAST (3) stroke subtype was cardioembolism (35%). The median admission NIHSS score was 12 (range, 5–23), and the median time from symptom onset to administration of an IV-tPA bolus was 143 min. The usual dosage of rt-PA was 0 9 mg/kg. However, in patients who could not afford complete costs of the drug, the dosage was lowered to 0 6–0 9 mg/kg (maximum 50 mg) based on previous data showing that low-dose IVrt-PA administered to Asian patients resulted in relatively good efficacy and safety compared with regular-dose therapy in Western patients (4, 5). Seventy-three (60 3%) patients received standard dose and 48 (39 7%) patients received lower dose (mean calculated IV-tPA dose for these patients was 0.62 mg/kg, range 0 6–0 86 mg/kg). We found that 52 (43%) of patients receiving rt-PA showed an mRS 0–1 at 3-months after receiving IV alteplase therapy, comparable with figures from NINDS (39%) (1). Symptomatic intracranial haemorrhage within 36 h occurred in only (4 1%) of treated patients and 10 (8%) of treated patients died within 3-months of stroke. The majority of patients with IS presenting to our stroke units were ineligible for treatment as only 8 7% of our patients arrived within 3 h. The principal reasons for this may be a lack of awareness of stroke symptoms and a poorly developed ambulance system. Moreover, 5% of eligible patients did not give consent because of a fear of excessive bleeding risk. Our study provides further confirmatory evidence of the safety and feasibility of IV-tPA for treatment in Asian patients with acute IS. More needs to be done to improve public awareness and organisation of services to enable more people to be eligible for treatment.

Intravenous thrombolysis.

Photodynamic inactivation and its application in food preservation

New Horizons in Microbiological Food Safety: Ultraefficient Photodynamic Inactivation Based on a Gallic Acid Derivative and UV-A Light and Its Application with Electrospun Cyclodextrin Nanofibers

Blackthorn fruit peel polyphenol extracts and photodynamic effect under blue light against Listeria monocytogenes

Photoinactivation of microorganisms using bacteriochlorins as photosensitizers

In vitro antimicrobial, antibiofilm photodynamic activity, and molecular dynamic simulations of tetra-cationic porphyrinmembrane interactions against foodborne microorganisms

In Situ Disinfection Through Photoinspired Radical Oxygen Species Storage and Thermal-Triggered Release from Black Phosphorous with Strengthened Chemical Stability

Evaluation of ferromagnetic materials for low-frequency hysteresis heating of tumours.

Recent advances in engineered polymeric materials for efficient photodynamic inactivation of bacterial pathogens

Efficient Strategies to Use β-Cationic Porphyrin-Imidazolium Derivatives in the Photoinactivation of Methicillin-Resistant Staphylococcus aureus

Action of photodynamic inactivation in antibiotic failures

In Vitro Antimicrobial Photodynamic Therapy for Pseudomonas aeruginosa (P. aeruginosa) and methicillin-resistant Staphylococcus aureus (MRSA) Inhibition Using a Green Light Source

Amphiphilic Tetracationic Porphyrins Are Exceptionally Active Antimicrobial Photosensitizers: in Vitro and in Vivo Studies with the Free-Base and Pd-chelate

Antimicrobial photodynamic therapy against Escherichia coli by exploiting endogenously produced Protoporphyrin IX- In vitro study

Polyphenolic natural products as photosensitizers for antimicrobial photodynamic therapy: recent advances and future prospects

Pulsed-light system as a novel food decontamination technology: a review

Emerging trends in the application of riboflavin-mediated photodynamic inactivation for food preservation

Recent advances on the application of UV-LED technology for microbial inactivation: Progress and mechanism

Photodynamic inactivation and its effects on the heterogeneity of bacterial resistance

Fast Broad-Spectrum Staining and Photodynamic Inhibition of Pathogenic Microorganisms by a Water-Soluble Aggregation-Induced Emission Photosensitizer

Photodynamic Inactivation Using Natural Bioactive Compound Prevents and Disrupts the Biofilm Produced by Staphylococcus saprophyticus